Familial partial lipodystrophy type 2 and obesity, two adipose tissue pathologies with different inflammatory profiles

The transition to metabolically unhealthy obesity (MUO) is driven by the limited expandability of adipose tissue (AT). Familial Partial Lipodystrophy type 2 (FPLD2) is an alternative model for AT dysfunction that is suitable for comparison with obesity. While MUO is associated with low-grade systemi...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology and metabolic syndrome 2023-04, Vol.15 (1), p.77-77, Article 77
Main Authors: Treiber, Guillaume, Gonthier, Marie-Paule, Guilleux, Alice, Medjane, Samir, Bonfanti, Oriane, Cogne, Muriel, Meilhac, Olivier, Nobecourt, Estelle
Format: Article
Language:English
Subjects:
Adipocytokines
Adiponectin
Adipose tissue
Adipose tissues
Age
Biomarkers
Body fat
Body mass index
Brief Report
Cholesterol
Comparative analysis
Diabetes
Diabetes mellitus
Disease
Dunnigan
Enzymes
Genetic aspects
High density lipoprotein
Hypertension
Inflammation
Insulin resistance
Interleukin 6
Leptin
Life Sciences
Lipodystrophy
Liver
Metabolism
Monocyte chemoattractant protein 1
Obesity
Plasma levels
Tumor necrosis factor-α
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The transition to metabolically unhealthy obesity (MUO) is driven by the limited expandability of adipose tissue (AT). Familial Partial Lipodystrophy type 2 (FPLD2) is an alternative model for AT dysfunction that is suitable for comparison with obesity. While MUO is associated with low-grade systemic inflammation, studies of inflammation in FPLD2 have yielded inconsistent results. Consequently, comparison of inflammation markers between FPLD2 and obesity is of great interest to better understand the pathophysiological defects of FPLD2. To compare the levels of inflammatory biomarkers between a population of patients with FPLD2 due to the same 'Reunionese' LMNA variant and a population of patients with obesity (OB group). Adiponectin, leptin, IL-6, TNF-α and MCP-1 plasma levels were measured by enzyme-linked immuno assays for 60 subjects with FPLD2 and for 60 subjects with obesity. The populations were closely matched for age, sex, and diabetic status. Metabolic outcomes were similar between the two populations. Adiponectinemia and leptinemia were lower in the FPLD2 group than in the OB group (p 
ISSN:1758-5996
1758-5996
DOI:10.1186/s13098-023-01055-4